KaloBios stock soars after investment from infamous drug CEO

Posted online November 20, 2015 | 11:43 am

Shares of cancer drug developer KaloBios Pharmaceuticals are skyrocketing after Martin Shkreli, the infamous CEO behind Turing Pharmaceuticals, took a majority stake in the company.

After KaloBios disclosed an investor group led by Shkreli acquired most of its stock, shares surged to as high as $11.87 after closing Wednesday at $2.07.

The former hedge fund manager came under fire in September when his company raised the price of parasitic infection drug Daraprim by over 5,000 percent.

Read more from The Associated Press.

Comments

No comments on this story |

Please log in to add your comment

Least of These executive director exits

Editors' Pick

Open for Business: EarthWise Pet

The first southwest Missouri location of EarthWise Pet, a national chain of pet supply stores, opened; Grey Oak Investments LLC relocated; and Hot Bowl by Everyday Thai LLC got its start.

Most Read